adenine has been researched along with abt-199 in 121 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 67 (55.37) | 24.3611 |
| 2020's | 54 (44.63) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, JR; O'Brien, SM; Porter, DL | 1 |
| Niemann, CU | 1 |
| Abdul-Hay, M; Desai, AV; El-Bakkar, H | 1 |
| Cao, Y; Castillo, JJ; Chen, J; Davids, MS; Hatjiharissi, E; Hunter, ZR; Kanan, S; Liu, X; Treon, SP; Tsakmaklis, N; Xu, L; Yang, G | 1 |
| Amiot, M; Brosseau, C; Chiron, D; Dousset, C; Le Gouill, S; Maïga, S; Moreau, P; Pellat-Deceunynck, C; Touzeau, C | 1 |
| Balakrishnan, K; Cervantes-Gomez, F; Gandhi, V; Keating, MJ; Lamothe, B; Wierda, WG; Woyach, JA | 1 |
| Gaidano, G; Ghia, P; Malcikova, J; Montserrat, E; Moreno, C; Pospisilova, S; Rosenquist, R; Rossi, D; Stamatopoulos, K; Sutton, LA; Tausch, E | 1 |
| Bojarczuk, K; Efremov, DG; Gobessi, S; Innocenti, I; Laurenti, L; Pozzato, G; Sasi, BK | 1 |
| Brown, JR; Hallek, MJ; Pagel, JM | 1 |
| Andrews, DW; Brauer, PM; Hariharan, S; Leber, B; Oakes, CC; Oppermann, S; Shi, Y; Spaner, DE; Ylanko, J; Zúñiga-Pflücker, JC | 1 |
| Cramer, P; Eichhorst, B; Hallek, M; Reinhardt, HC | 1 |
| Awan, FT; Ayala, E; El-Asmar, J; Hamadani, M; Kharfan-Dabaja, MA | 1 |
| Brown, JR; Davids, MS; Deng, J; Fernandes, SM; Isik, E; Letai, A | 1 |
| Abrisqueta, P; Bosch, F; Delgado, J; García-Marco, JA; Giraldo, P; González, M; Hernández-Rivas, JA; Jarque, I; Loscertales Pueyo, J; Martínez, R; Ramírez Payer, Á; Terol, MJ; Yáñez, L | 1 |
| Agarwal, R; Arnau, GM; Blombery, P; Chan, YC; Dawson, MA; Dawson, SJ; Doig, K; Ftouni, S; Hunter, T; Jiang, D; Jones, K; Lam, E; Papenfuss, AT; Petrone, P; Semple, T; Seymour, JF; Silva, MJ; Sinha, D; Tam, CS; Vedururu, R; Wall, M; Wallach, E; Westerman, D; Wong, SQ; Yeh, P; Zivanovic, A | 1 |
| Kaur, V; Swami, A | 1 |
| Hill, BT; Waldron, M; Winter, A | 1 |
| Molica, S | 1 |
| Bence-Bruckler, I; Coutre, S; Delage, R; Owen, CJ; Shustik, C; Toze, CL | 1 |
| Apatira, M; Beaupre, DM; Chang, BY; Chen, CT; Cheung, LWK; Eckert, K; Ezell, SA; Hsieh, S; Hsu, SJ; Kuo, HP; Schweighofer, KJ; Sirisawad, M; Versele, M | 1 |
| Barr, PM; Brander, DM; Cheson, BD; Claxton, DF; Cruz, AL; Daniel, C; Fanning, M; Foon, K; Gashonia, L; Goy, A; Henick Bachow, S; Hill, BT; Howlett, C; Isaac, K; Kennard, KH; Kiselev, P; Lamanna, N; Lenhart, J; Mato, AR; Nabhan, C; Pu, JJ; Schuster, SJ; Skarbnik, AP; Svoboda, J; Timlin, C; Ujjani, CS; Winter, AM; Yacur, M; Zent, CS | 1 |
| Kharfan-Dabaja, MA; Rafei, H | 1 |
| Edelmann, J; Gribben, JG | 1 |
| Albericio, F; Cosialls, AM; de la Banda, E; Gil, J; González-Barca, EM; González-Gironès, DM; Iglesias-Serret, D; Lavilla, R; Núñez-Vázquez, S; Pomares, H; Pons, G; Preciado, S; Saura-Esteller, J | 1 |
| Conaway, MR; Petroni, GR; Portell, CA; Wages, NA; Williams, ME | 1 |
| Ayres, ML; Balakrishnan, K; Cheung, JP; Gandhi, V; Gay, J; Ivan, C; Keating, MJ; Lamothe, B; Marszalek, JR; Morse, J; Nelson, M; Patel, VK; Wierda, WG | 1 |
| Burger, JA; Thompson, PA | 1 |
| Davids, MS | 1 |
| Barr, PM; Byrd, JC; Cheson, BD; Choi, M; Chyla, B; Coutre, S; Davids, MS; Furman, RR; Humerickhouse, RA; Jones, JA; Lamanna, N; Mato, AR; Potluri, J; Salem, AH; Verdugo, M; Wierda, WG; Woyach, J; Zhou, L | 1 |
| Foà, R; Mauro, FR | 1 |
| Jiang, H; Li, G; Lwin, T; Moscinski, L; Ren, Y; Shah, B; Tao, J; Zhao, X | 1 |
| Eichhorst, B; Hallek, M; Shanafelt, TD | 1 |
| Agarwal, R; Anderson, MA; Bressel, M; Burbury, K; Dawson, MA; Dawson, SJ; Di Iulio, J; Dreyling, M; Handunnetti, S; Hicks, RJ; Lade, S; Pott, C; Roberts, AW; Seymour, JF; Tam, CS; Turner, G; Westerman, D | 1 |
| Mato, A; Rhodes, J; Sharman, JP | 1 |
| Killock, D | 1 |
| Agarwal, R; Dawson, MA; Dreyling, M; Tam, CS | 1 |
| Woyach, JA | 3 |
| Awan, FT; Byrd, JC; Heerema, NA; Hoffman, C; Huang, Y; Jones, JA; Lozanski, G; Lucas, M; Maddocks, KJ; Moran, ME; Reid, MA; Rogers, KA; Ruppert, AS; Whitlow, WT; Woyach, JA | 1 |
| Estrov, Z; Jain, P; Kanagal-Shamanna, R; Konoplev, S; Zuo, Z | 1 |
| Davids, MS; Lampson, BL | 1 |
| Bonina, S; Cafforio, L; Del Giudice, I; Foà, R; Gaidano, G; Guarini, A; Ilari, C; Mariglia, P; Marinelli, M; Mauro, FR; Messina, M; Peragine, N; Raponi, S | 1 |
| Agarwal, R; Anderson, MA; Bell, CC; Blombery, P; Chan, YC; Dawson, MA; Dawson, SJ; Ftouni, S; Gilan, O; Gray, DHD; Huang, DCS; Hunter, T; Knezevic, K; Lam, EYN; Li, J; Pott, C; Rayeroux, K; Roberts, AW; Seymour, JF; Tam, CS; Teh, CE; Thijssen, R; Vassiliadis, D; Wall, M; Wong, SQ; Yeh, P; Zordan, A | 1 |
| Brown, JR | 1 |
| Brown, JR; Kater, AP | 1 |
| Feng, J; Hu, R; Jiang, H; Lin, N; Liu, X; Wang, L; Yan, Y; Zhang, B; Zhang, Q; Zhou, X | 1 |
| Arribas, AJ; Bertoni, F; Cascione, L; Curti, E; Gaudio, E; Priebe, V; Rossi, D; Spriano, F; Stathis, A; Tarantelli, C; Zhang, L; Zucca, E | 1 |
| Patil, N; Went, RG | 1 |
| Choi, CM; Choi, YJ; Hong, JY; Kim, DH; Lee, JC; Rho, JK; Suh, C; Yoon, DH | 1 |
| Bhargava, P; Byrd, JC; Chanan-Khan, AA; Darif, M; Dreiling, LK; Ferrante, L; Furman, RR; Hillmen, P; Howes, A; James, DF; Jones, J; Kay, NE; Londhe, A; Mobasher, M; Mun, Y; Ni, A; Rabe, KG; Reddy, V; Seymour, JF; Shanafelt, TD; Sharman, JP; Soumerai, JD; Stark, T; Xing, G; Zelenetz, AD | 1 |
| Alvarado, Y; Ayala, A; Borthakur, G; Bose, P; Burger, J; Cruz, N; DiNardo, C; Estrov, Z; Ferrajoli, A; Fowler, N; Gandhi, V; Garg, N; Jabbour, E; Jain, N; Jorgensen, J; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Keating, M; Konopleva, M; Ohanian, M; Patel, K; Pemmaraju, N; Plunkett, W; Sasaki, K; Sondermann, K; Takahashi, K; Thompson, P; Wang, X; Wei, C; Wierda, W; Yilmaz, M | 1 |
| Wiestner, A | 1 |
| Wierda, WG | 1 |
| Hanna, KS | 1 |
| Romero, D | 1 |
| Akritidou, MA; Anagnostopoulos, A; Belloni, D; Chartomatsidou, E; Ferrero, E; Ghia, P; Kotta, K; Ntoufa, S; Papakonstantinou, N; Rosenquist, R; Rovida, A; Stamatopoulos, K; Stavroyianni, N; Trangas, T | 1 |
| Bishop, R; Bloor, A; Boucher, R; Brock, K; Devereux, S; Fegan, C; Forconi, F; Fox, CP; Gribben, JG; Hillmen, P; MacDonald, D; McCaig, A; Munir, T; Muñoz-Vicente, S; Patten, PEM; Pettitt, A; Rawstron, AC; Schuh, A; Yates, FJ | 1 |
| Autore, F; Ciolli, S; Coscia, M; Cuneo, A; D'Arena, G; Del Poeta, G; Efremov, DG; Foà, R; Frustaci, A; Gentile, M; Ibatici, A; Innocenti, I; Laurenti, L; Levato, L; Mauro, FR; Morelli, F; Murru, R; Piciocchi, A; Reda, G; Rigolin, GM; Scarfò, L; Schiattone, L; Sportoletti, P; Tedeschi, A; Trentin, L | 1 |
| Kater, AP; Levin, MD; Niemann, CU | 1 |
| Gandhi, V; Jain, N; Wierda, W | 1 |
| Arias-Martínez, A; Carriles, C; Menárguez-Blanc, R; Ordóñez-Fernández, L; Rosado-María, MC | 1 |
| Huang, L; Li, JM; Wu, C; Xu, WB; Yan, H; Ye, CJ; Yu, Q | 1 |
| Andreadis, C; Fakhri, B | 1 |
| Aguilar-Company, J; Los-Arcos, I; Ruiz-Camps, I | 1 |
| Braggio, E; Call, TG; Ding, W; Fonder, AL; Hampel, PJ; Kay, NE; Kenderian, SS; Koehler, AB; Leis, JF; Muchtar, E; Parikh, SA; Rabe, KG; Schwager, SM; Slager, SL; Van Dyke, DL; Wang, Y; Witzig, TE | 1 |
| Eichhorst, B; Fürstenau, M; Hallek, M | 1 |
| Gutierrez, C; Wu, CJ | 1 |
| Danhof, S; Düll, J; Einsele, H; Grathwohl, D; Kortüm, M; Krummenast, F; Leicht, HB; Meckel, K; Nickel, K; Rasche, L; Rosenwald, A; Steinhardt, MJ; Zhou, X | 1 |
| Al-Sawaf, O; Eichhorst, B; Hallek, M | 1 |
| Agarwal, A; Chang, BH; Danilov, AV; Druker, BJ; Eide, CA; Kaempf, A; Kurtz, SE; Long, N; Mori, M; Tognon, CE; Tyner, JW | 1 |
| Blachly, JS; Byrd, JC; Doong, TJ; Gregory, CT; Larkin, K; Lozanski, A; Lozanski, G; Lucas, F; Misra, S; Ngankeu, A; Orwick, S; Ozer, HG; Rogers, KA; Sampath, D; Thangavadivel, S; Woyach, JA; Yilmaz, SA | 1 |
| Anderson, MA; Blombery, P; Handunnetti, SM; Kuss, BJ; Lew, TE; Lin, VS; Nguyen, T; Roberts, AW; Seymour, JF; Tam, CS; Westerman, DA | 1 |
| Suzumiya, J; Takizawa, J | 1 |
| De Silva, N; Droogendijk, J; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Gregor, M; Hallek, M; Hohloch, K; Illmer, T; Kater, AP; Langerbeins, P; Niemann, CU; Robrecht, S; Schöttker, B; Simon, F; Stilgenbauer, S; Tausch, E; van der Klift, M; van der Spek, E; von Tresckow, J; Wendtner, CM | 1 |
| Bax, DJC; Borst, J; Brown, JR; Chiodin, G; Dubois, J; Eldering, E; Fernandes, SM; Forconi, F; Haselager, MV; Kater, AP; Kielbassa, K; Tam, C; Ter Burg, J | 1 |
| Cramer, P; Eichhorst, B; Hallek, M; von Tresckow, J | 1 |
| Abruzzo, LV; Andersen, BL; Awan, FT; Banks, C; Bhat, SA; Byrd, JC; Dean, A; Grantier, C; Heerema, NA; Huang, Y; Jones, JA; Lozanski, G; Lucas, M; Maddocks, KJ; Rogers, KA; Ruppert, AS; Valentine, TR; Weiss, DM; Woyach, JA | 1 |
| Burger, JA; Khanlari, M; Liu, W; Medeiros, LJ; Tang, G; Tang, Z; Toruner, G; Xu, J | 1 |
| Gao, A; Gao, W; Huo, D; Ran, X; Sheng, Z; Song, S; Yu, M; Zhu, H | 1 |
| Dobber, JA; Kater, AP; Kersting, S; Levin, MD; Mattson, M; Mous, R; Nasserinejad, K; Niemann, CU; Ostrowski, SR; Svanberg, R; Tran, HTT | 1 |
| Bellido, M; Dobber, JA; Dompeling, EC; Dubois, J; Enggaard, L; Frederiksen, H; Janssens, A; Kater, AP; Kersting, S; Levin, MD; Mattsson, M; Mellink, CHM; Mous, R; Nasserinejad, K; Niemann, CU; Poulsen, CB; Ranti, J; Schjødt, I; Tran, HTT; Veldhuis, GJ | 1 |
| Anderson, MA; Blombery, P; Davis, JE; Handunnetti, SM; Koldej, RM; Ludford-Menting, M; Ritchie, DS; Roberts, AW; Seymour, JF; Sharpe, C; Tam, CS | 1 |
| Kater, AP; Kersting, S; Levin, MD; Mattsson, M; Nasserinejad, K; Niemann, CU; Ranti, J; Thi Tuyet Tran, H | 1 |
| Bartoli, L; Messori, A | 1 |
| Bodet-Milin, C; Bossard, C; Bouabdallah, K; Callanan, MB; Cartron, G; Casasnovas, O; Chiron, D; Gastinne, T; Herbaux, C; Le Gouill, S; McCulloch, R; Morschhauser, F; Nadal, N; Ragot, S; Rossi, C; Rule, S; Tchernonog, E; Tessoulin, B | 1 |
| Giannarelli, D; Molica, S; Montserrat, E | 1 |
| Smolej, L | 1 |
| Avsec, D; Gobec, M; Jakopin, Ž; Markovič, T; Mlinarič-Raščan, I; Nabergoj, S; Podgornik, H | 1 |
| Elsawa, SF; Ghazal, SM; Han, W; Karbalivand, M; Mallat, S; Matissek, SJ; Munshi, M; Reilly, BM; Sayed, M; Treon, SP; Walker, SR; Yang, G | 1 |
| Abreu, MM; Gouvea, J; Jewett, A; Ko, MW; Maharaj, D; Srinivasan, G | 1 |
| Maddocks, K | 1 |
| Baldwin, DA; Chen, Y; Franzen, CA; Gao, J; Khan, N; Larson, RA; Li, L; Lu, P; Ma, S; McClure, R; Nejati, R; Niu, N; Pei, J; Sukhanova, M; Tu, Y; Venkataraman, G; Wang, S; Wang, YL; Wasik, MA; Wu, W | 1 |
| Boidol, B; Caron, P; Chong, SJF; Davids, MS; Guillemette, C; Heintel, D; Herbaux, C; Hopfinger, G; Jäger, R; Jäger, U; Kazianka, L; Kornauth, C; Kubicek, S; Mayerhöfer, ME; Pemovska, T; Poulain, S; Raderer, M; Simonitsch-Klupp, I; Sperr, WR; Staber, PB; Tournilhac, O; Van der Kouwe, E | 1 |
| Boccadoro, M; Boccellato, E; Cassin, R; Coscia, M; Cuneo, A; De Paoli, L; Foà, R; Gaidano, G; Gentile, M; Griggio, V; Laurenti, L; Marchetti, M; Mauro, FR; Montalbano, MC; Murru, R; Orsucci, L; Pennese, E; Perutelli, F; Porrazzo, M; Reda, G; Rigolin, GM; Rivela, P; Salvetti, C; Scarfò, L; Schiattone, L; Tedeschi, A; Trentin, L; Vassallo, F; Visentin, A; Vitale, C; Zamprogna, G | 1 |
| Bhalla, KN; Birdwell, C; Burger, J; Coarfa, C; Crews, CM; Davis, JA; Deng, Q; Ferrajoli, A; Fiskus, W; Green, MR; Jain, N; Jin, W; Khoury, JD; Lara, BH; Mill, CP; Perera, D; Saenz, DT; Yang, H | 1 |
| Haioun, C; Lemonnier, F; Roulin, L | 1 |
| Fu, X; Li, L; Li, X; Li, Z; Sun, Z; Wang, X; Zhang, L; Zhang, M; Zhang, X; Zhou, Z | 1 |
| Anderson, MA; Juneja, S; Leitinger, EJ; Nelson, N; Wright, RM | 1 |
| Al-Sawaf, O; Cramer, P; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Giza, A; Hallek, M; Kneba, M; Langerbeins, P; Pelzer, BW; Robrecht, S; Schneider, C; Stilgenbauer, S; Tausch, E; von Tresckow, J; Wendtner, CM | 1 |
| Alvarado, Y; Ayala, A; Borthakur, G; Bose, P; Burger, JA; Cruz, N; DiNardo, C; Estrov, Z; Ferrajoli, A; Fowler, N; Gandhi, V; Garg, N; Jabbour, E; Jain, N; Jorgensen, J; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Keating, M; Konopleva, M; Ohanian, M; Patel, K; Pemmaraju, N; Plunkett, W; Sasaki, K; Takahashi, K; Thompson, P; Wang, SA; Wang, W; Wang, X; Wei, C; Wierda, WG; Yilmaz, M | 1 |
| Thangavadivel, S; Woyach, JA | 1 |
| Mato, AR; Thompson, MC | 1 |
| Alpár, D; Bödör, C; Deák, B; Demeter, J; Farkas, P; Gángó, A; Hanna, E; Kiss, R; Kotmayer, L; Lévai, D; Matolcsy, A; Mátrai, Z; Timár, B | 1 |
| Balasubramanian, S; Cretenet, G; Eldering, E; Kater, AP; Leverson, JD; Martens, AW; Slinger, E | 1 |
| Alonso, C; Ángel Hernández-Rivas, J; Bastidas, G; Bastos-Oreiro, M; Bocanegra, A; Carpio, C; Comai, A; Cordoba, R; De Nicolás, R; Del Campo, R; Fernández-Cruz, A; García-Suárez, J; Grande, C; Jiménez-Ubieto, A; López-Guillermo, A; López-Jiménez, J; Luis Plana, J; Marquet, J; Martín, X; Martínez-López, J; Mas-Ochoa, C; Morillo, D; Navarro-Matilla, B; Núñez, L; Prat, M; Romero, S; Ruiz-Camps, I; Seri, C; Serna, Á; Stefania Infante, M; Vásquez, L; Villafuerte, P | 1 |
| Allan, JN; Badoux, XC; Dean, JP; Flinn, I; Ghia, P; Jackson, S; Jacobs, R; James, DF; Kipps, TJ; Kuss, BJ; Moreno, C; Ninomoto, J; Opat, S; Pagel, JM; Pak, Y; Siddiqi, T; Szafer-Glusman, E; Tam, CS; Tedeschi, A; Wierda, WG; Zhou, C | 1 |
| O'Brien, SM | 1 |
| Budde, LE; Chen, RW; Cohen, JB; Kahl, BS; Petroni, GR; Portell, CA; Varhegyi, NE; Wages, NA; Williams, ME | 1 |
| Bishton, M; Chen, R; Chong, G; Collins, GP; Eckert, K; Eliadis, P; Jurczak, W; Karlin, L; Lee, Y; Neuenburg, JK; Peyrade, F; Ramchandren, R; Tam, CS; Wang, M; Wu, KL | 1 |
| Shah, HR; Stephens, DM | 1 |
| Bloehdorn, J; Böttcher, S; Döhner, H; Dreger, P; Dürig, J; Edenhofer, S; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Hallek, M; Huber, H; Illert, AL; Illmer, T; Kneba, M; Niemann, CU; Ritgen, M; Robrecht, S; Schneider, C; Stilgenbauer, S; Tausch, E; von Tresckow, J; Zhang, C | 1 |
| Allan, JN; Bannerji, R; Barr, PM; Dean, JP; Ghia, P; Jackson, S; Jacobs, R; Kipps, TJ; Kuss, BJ; Moreno, C; Ninomoto, J; Opat, S; Russell, K; Siddiqi, T; Szafer-Glusman, E; Tam, CS; Tedeschi, A; Trentin, L; Wierda, WG; Zhou, C | 1 |
| Ferrarini, I; Gandini, F; Rigo, A; Zapparoli, E | 1 |
| Rogers, KA; Woyach, JA | 1 |
| Bellido, M; Brieghel, C; Dobber, JA; Dompeling, EC; Dubois, J; Enggaard, L; Frederiksen, H; Janssens, A; Kater, AP; Kersting, S; Levin, MD; Mattsson, M; Mellink, CHM; Mous, R; Nasserinejad, K; Niemann, CU; Poulsen, CB; Ranti, J; Schjødt, I; Tran, HTT; van der Kevie-Kersemaekers, AF; Veldhuis, GJ | 1 |
| Braggio, E; Call, TG; Ding, W; Hampel, PJ; Kay, NE; Kenderian, SS; Koehler, AB; Leis, JF; Muchtar, E; Parikh, SA; Parrondo, R; Rabe, KG; Schwager, SM; Shi, M; Slager, SL; Wang, Y | 1 |
| Allan, JN; Barr, PM; Ghia, P; Grigg, AP; Jacobs, R; Krigsfeld, G; Ninomoto, J; O'Brien, S; Tam, CS; Tedeschi, A; Vallisa, D; Walker, P; Wierda, WG; Zhou, C | 1 |
| Bose, P; Ferrajoli, A; Garg, N; Jain, N; Jorgensen, JL; Kadia, TM; Keating, MJ; Pemmaraju, N; Peterson, CB; Short, NJ; Thompson, PA; Wang, SA; Wierda, WG | 1 |
30 review(s) available for adenine and abt-199
| Article | Year |
|---|---|
Novel treatments for chronic lymphocytic leukemia and moving forward.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Small Molecule Libraries; Sulfonamides; Vidarabine | 2014 |
[Targeted treatment of chronic lymphocytic leukaemia].
Topics: Adenine; Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Morpholines; Oxazines; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Sulfonamides | 2014 |
Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Topics: Adenine; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Flavonoids; Humans; Immunologic Factors; Indolizines; Isoquinolines; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyridinium Compounds; Pyrimidines; Quinazolinones; Receptors, Antigen, T-Cell; Sulfonamides; Thalidomide | 2015 |
Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Sulfonamides; Vidarabine | 2016 |
Current strategies to create tailored and risk-adapted therapies for CLL patients.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase II as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Precision Medicine; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Risk Factors; Sulfonamides | 2016 |
Current state of hematopoietic cell transplantation in CLL as smart therapies emerge.
Topics: Adenine; Allografts; Antibodies, Monoclonal; Antibodies, Neoplasm; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Human, Pair 17; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Smith-Magenis Syndrome; Sulfonamides | 2016 |
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Diarrhea; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nausea; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Sulfonamides | 2017 |
Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.
Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Interactions; Food-Drug Interactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Sulfonamides | 2017 |
Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Sulfonamides | 2017 |
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Drug Therapy; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Recurrence; Sulfonamides; Transplantation, Homologous | 2017 |
Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies.
Topics: Adenine; Allografts; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Human, Pair 17; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Smith-Magenis Syndrome; Sulfonamides; Tumor Suppressor Protein p53 | 2018 |
Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Remission Induction; Sulfonamides; Tumor Suppressor Protein p53 | 2017 |
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Drug Design; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Sulfonamides | 2018 |
How should we sequence and combine novel therapies in CLL?
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Smith-Magenis Syndrome; Sulfonamides | 2017 |
Chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Diagnosis, Differential; Genetic Predisposition to Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Recurrence; Risk Factors; Sulfonamides; Survival Analysis; Treatment Outcome | 2018 |
Monitoring and Management of Toxicities of Novel B Cell Signaling Agents.
Topics: Adenine; Antineoplastic Agents; Atrial Fibrillation; B-Lymphocytes; Bridged Bicyclo Compounds, Heterocyclic; Hemorrhage; Humans; Lymphoma, Non-Hodgkin; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Sulfonamides | 2018 |
Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Patient Selection; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Sulfonamides | 2018 |
Relapsed CLL: sequencing, combinations, and novel agents.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase I as Topic; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Sulfonamides | 2018 |
Updates in the management of chronic lymphocytic leukemia/small lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Disease Management; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2020 |
[Venetoclax combined with rituximab in the treatment of ibrutinib-resistant patient with chronic lymphocytic leukemia: a case report and literature reviews].
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides | 2019 |
Risk of infection associated with new therapies for lymphoproliferative syndromes.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Communicable Disease Control; Humans; Immune Checkpoint Inhibitors; Infections; Lymphoproliferative Disorders; Piperidines; Purines; Pyrazines; Quinazolinones; Risk; Rituximab; Sulfonamides; Syndrome | 2020 |
Clonal dynamics in chronic lymphocytic leukemia.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Genome-Wide Association Study; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Sulfonamides; Transcriptome; Whole Genome Sequencing | 2019 |
Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Sulfonamides | 2019 |
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Neoplasm, Residual; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides; Vidarabine | 2020 |
[Current diagnosis and treatment of chronic lymphocytic leukaemia].
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Comorbidity; Drug Approval; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Staging; Piperidines; Prognosis; Purines; Quinazolinones; Rituximab; Smith-Magenis Syndrome; Sulfonamides | 2020 |
Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Prospective Studies; Pyrazines; Sulfonamides | 2020 |
Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Mutation; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Sulfonamides; Tumor Suppressor Protein p53 | 2021 |
Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Randomized Controlled Trials as Topic; Rituximab; Sulfonamides | 2021 |
Genomics of Resistance to Targeted Therapies.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Genomics; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcr; Sulfonamides | 2021 |
Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Sulfonamides | 2021 |
20 trial(s) available for adenine and abt-199
| Article | Year |
|---|---|
Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted Agents.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Dose-Response Relationship, Drug; Humans; Lymphoma, Mantle-Cell; Models, Theoretical; Molecular Targeted Therapy; Piperidines; Pyrazoles; Pyrimidines; Research Design; Sulfonamides; Treatment Outcome | 2017 |
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Sulfonamides; Time Factors; Treatment Outcome; United States | 2018 |
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Topics: Adenine; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Female; Historically Controlled Study; Humans; Intention to Treat Analysis; Lymph Nodes; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Neoplasm, Residual; Piperidines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Sulfonamides; Survival Rate | 2018 |
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2018 |
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Induction Chemotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Mutation; Neoplasm, Residual; Neutropenia; Piperidines; Pyrazoles; Pyrimidines; Remission Induction; Sulfonamides | 2019 |
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Sulfonamides | 2019 |
COVID-19 among fit patients with CLL treated with venetoclax-based combinations.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Bridged Bicyclo Compounds, Heterocyclic; Coronavirus Infections; COVID-19; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pandemics; Piperidines; Pneumonia, Viral; Prognosis; Pyrazoles; Pyrimidines; Rituximab; SARS-CoV-2; Sulfonamides | 2020 |
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2020 |
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; CD4 Lymphocyte Count; Cognition; Female; Follow-Up Studies; Humans; Hypertension; Hyponatremia; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Piperidines; Progression-Free Survival; Quality of Life; Remission Induction; Retreatment; Sulfonamides; Survival Rate; Thrombocytopenia; Young Adult | 2020 |
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Sulfonamides; Treatment Outcome | 2021 |
Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL)
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Creatinine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prospective Studies; Receptor Tyrosine Kinase-like Orphan Receptors; Recurrence; Sulfonamides; Tumor Suppressor Protein p53 | 2020 |
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Female; Follow-Up Studies; Genes, p53; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm, Residual; Piperidines; Progression-Free Survival; Prospective Studies; Sulfonamides; Treatment Outcome | 2021 |
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Purines; Quinazolinones; Sulfonamides | 2021 |
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Female; Gene Deletion; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Progression-Free Survival; Prospective Studies; Sulfonamides; Tumor Suppressor Protein p53 | 2021 |
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Sulfonamides | 2021 |
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cohort Studies; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Sulfonamides; Survival Analysis | 2021 |
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.
Topics: Adenine; Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Sulfonamides | 2022 |
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Sulfonamides; Treatment Outcome | 2021 |
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Sulfonamides; Survival Rate | 2022 |
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2022 |
71 other study(ies) available for adenine and abt-199
| Article | Year |
|---|---|
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bridged Bicyclo Compounds, Heterocyclic; Drug Synergism; Humans; Membrane Proteins; Piperidines; Proto-Oncogene Proteins; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, CXCR4; Sulfonamides; Waldenstrom Macroglobulinemia | 2015 |
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Apoptosis; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; CD40 Antigens; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymph Nodes; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; NF-kappa B; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Sulfonamides; Tumor Microenvironment | 2015 |
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Cell Activating Factor; bcl-X Protein; Bendamustine Hydrochloride; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Female; Gene Expression Regulation, Leukemic; Humans; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplastic Cells, Circulating; Nitrophenols; Piperazines; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Sulfonamides | 2015 |
Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alleles; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Class I Phosphatidylinositol 3-Kinases; Gene Expression; Gene Frequency; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Prognosis; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Sulfonamides; Tumor Suppressor Protein p53 | 2016 |
BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Oxazines; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Sulfonamides | 2016 |
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.
Topics: Adenine; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cellular Microenvironment; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Imaging, Three-Dimensional; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Quinazolinones; Reproducibility of Results; Signal Transduction; Stromal Cells; Sulfonamides; Sunitinib; Up-Regulation | 2016 |
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bcl-2-Like Protein 11; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitochondria; Molecular Targeted Therapy; Neoplasm Proteins; Peptide Fragments; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Pyrimidines; Sulfonamides | 2017 |
Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Sulfonamides | 2017 |
Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Baculoviral IAP Repeat-Containing 3 Protein; Bridged Bicyclo Compounds, Heterocyclic; Circulating Tumor DNA; Clonal Evolution; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloid Differentiation Factor 88; Phosphoproteins; Piperidines; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyrimidines; Receptor, Notch1; RNA Splicing Factors; Sulfonamides; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Mice; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2017 |
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperidines; Proportional Hazards Models; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Retrospective Studies; Sulfonamides; Treatment Outcome; Young Adult | 2017 |
The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax.
Topics: Adenine; Aminoimidazole Carboxamide; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Hydrocarbons, Fluorinated; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Prohibitins; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Repressor Proteins; Ribonucleosides; Sulfonamides; Thiazolidines; Tumor Cells, Cultured; Up-Regulation | 2017 |
Appendix 4: Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017 (www.esmo.org/Guidelines/Haematological-Malignancies).
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Sequence Deletion; Sulfonamides; Tumor Suppressor Protein p53 | 2017 |
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
Topics: Adenine; Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cell Movement; Chemokine CCL3; Chemokine CCL4; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Sulfonamides | 2018 |
Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2018 |
Venetoclax Data Prompt Rethink of CLL Therapy.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2018 |
Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Female; Humans; Lymphoma, Mantle-Cell; Male; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides; Survival Rate; TOR Serine-Threonine Kinases | 2019 |
Targeted combination has synergy in MCL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2018 |
Counterpoint: Does Chemoimmunotherapy Still Have a Role in CLL? Chemotherapy Can Be Eliminated in the Management of CLL.
Topics: Adenine; Antineoplastic Agents, Immunological; Bridged Bicyclo Compounds, Heterocyclic; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Remission Induction; Sulfonamides | 2018 |
Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2018 |
A new triple threat to CLL.
Topics: Adenine; Adult; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2018 |
Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Cell Survival; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Sulfonamides; Tumor Suppressor Protein p53 | 2019 |
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.
Topics: Activating Transcription Factor 3; Adenine; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Chromatin; Chromosomal Proteins, Non-Histone; Circulating Tumor DNA; Cohort Studies; DNA Helicases; Drug Resistance, Neoplasm; Genome, Human; Humans; Lymphoma, Mantle-Cell; Models, Biological; Mutation; Nuclear Proteins; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Sulfonamides; Transcription Factors; Treatment Outcome | 2019 |
Ibrutinib: searching for a partner drug.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides; Treatment Outcome | 2019 |
The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Female; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice, Nude; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Ribonucleoproteins; Ribosomal Protein S6; Signal Transduction; SS-B Antigen; Sulfonamides; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Drug Synergism; Humans; Hydrazines; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Niacinamide; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides; Triazoles; Tumor Cells, Cultured | 2019 |
Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors.
Topics: Adenine; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Substitution; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Retreatment; Rituximab; Signal Transduction; Sulfonamides; Treatment Outcome | 2019 |
Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lymphoma, Mantle-Cell; Phosphorylation; Piperidines; Pyrazoles; Pyrimidines; RNA Polymerase II; Sulfonamides; Triazoles | 2019 |
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Topics: Adenine; Antineoplastic Agents; beta 2-Microglobulin; Bridged Bicyclo Compounds, Heterocyclic; Databases, Factual; Female; Hemoglobins; Humans; Immunotherapy; L-Lactate Dehydrogenase; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Proportional Hazards Models; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Sulfonamides; Survival Rate | 2019 |
Ibrutinib and Venetoclax - Doubling Down on CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2019 |
Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Patient Selection; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides; Treatment Outcome; Vidarabine | 2019 |
New first-line options in CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2019 |
Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Bridged Bicyclo Compounds, Heterocyclic; Down-Regulation; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Histones; Humans; Indazoles; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyridones; Pyrimidines; Quinazolinones; Signal Transduction; Sulfonamides; Tumor Microenvironment | 2019 |
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Disease Progression; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Retrospective Studies; Sulfonamides | 2019 |
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2019 |
Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2019 |
Can Combination Targeted Therapy Bring About Another Paradigm Shift in Chronic Lymphocytic Leukemia?
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides | 2019 |
Autoimmune hemolytic anemia, adverse event to venetoclax.
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Salvage Therapy; Sulfonamides; Vincristine | 2019 |
CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLL.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Clinical Trials, Phase III as Topic; Frail Elderly; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides; Survival Rate; Treatment Outcome | 2019 |
Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
Topics: Adenine; Aged; Aged, 80 and over; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides; Survival Rate | 2020 |
Relapsed disease and aspects of undetectable MRD and treatment discontinuation.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Sulfonamides | 2019 |
Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Remission Induction; Salvage Therapy; Sulfonamides | 2020 |
[Chronic lymphocytic leukemia].
Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Risk Factors; Sulfonamides | 2020 |
Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Humans; Leukemia, Myeloid, Acute; Mice; Piperidines; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Sulfonamides; Xenograft Model Antitumor Assays | 2020 |
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phospholipase C gamma; Piperidines; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2020 |
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Disease Progression; Drug Evaluation; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Retrospective Studies; Salvage Therapy; Sulfonamides; Treatment Outcome | 2020 |
LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Female; Gene Deletion; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Lipoprotein Lipase; Male; Middle Aged; Neoplasm Proteins; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Risk Assessment; Rituximab; Sulfonamides; Treatment Outcome; Tumor Suppressor Protein p53; ZAP-70 Protein-Tyrosine Kinase | 2020 |
Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Hemostasis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Sulfonamides | 2020 |
Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy.
Topics: Adenine; Adult; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; Piperidines; Pyrimidines; Sulfonamides | 2020 |
Restricted mean survival time in patients with chronic lymphocytic leukemia treated with chemotherapy-free regimens as first line.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Pyrazines; Sulfonamides; Survival Rate | 2021 |
EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells.
Topics: Adenine; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Dose-Response Relationship, Drug; Drug Synergism; Humans; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Piperidines; Purines; Pyrrolidinones; Quinazolinones; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Tetrazoles; U937 Cells | 2021 |
Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.
Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lymphoma, B-Cell; Molecular Targeted Therapy; Nerve Tissue Proteins; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Receptors, Cell Surface; Sulfonamides; Waldenstrom Macroglobulinemia | 2021 |
Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV- Unmutated Chronic Lymphocytic Leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Immunologic Factors; Immunotherapy; Interleukin-2; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperidines; Precision Medicine; Prognosis; Remission Induction; Sulfonamides | 2020 |
Building on BTK inhibition in MCL.
Topics: Adenine; Adult; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrimidines; Sulfonamides | 2021 |
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Protein Kinase Inhibitors; Sulfonamides; Tumor Cells, Cultured | 2021 |
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Prolymphocytic; Piperidines; Sulfonamides | 2021 |
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; Piperidines; Proteins; Proteolysis; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse/refractory mantle cell lymphoma.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Lymphoma, Mantle-Cell; Male; Neoplasm Recurrence, Local; Piperidines; Splenic Rupture; Sulfonamides; Treatment Failure; Withholding Treatment | 2021 |
Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Piperidines; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Treatment Outcome | 2021 |
Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Immunophenotyping; Lymphoma, Mantle-Cell; Male; Middle Aged; Phenotype; Piperidines; Sulfonamides | 2021 |
Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Female; Genes, p53; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mutation; Piperidines; Prognosis; Proto-Oncogene Proteins c-bcl-2; Risk Factors; Sulfonamides | 2022 |
Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia.
Topics: Adenine; Animals; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidines; Proto-Oncogene Proteins; Pyrazoles; Pyrimidines; Sulfonamides | 2021 |
Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.
Topics: Adenine; Adolescent; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Immunocompromised Host; Infections; Lymphopenia; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazines; Quinazolinones; Retrospective Studies; Risk Factors; Sulfonamides; Young Adult | 2021 |
Lessons learned from the CAPTIVATE trial of ibrutinib plus venetoclax in CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Sulfonamides | 2021 |
Is there a role for anti-CD20 antibodies in CLL?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents; Antineoplastic Agents, Immunological; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors; Pyrazines; Rituximab; Sulfonamides | 2021 |
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Piperidines; Sulfonamides | 2022 |
Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Sulfonamides | 2022 |
A CAPTIVATE-ing new regimen for CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Sulfonamides | 2022 |
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Retrospective Studies; Sulfonamides | 2022 |
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Creatinine; Cytoreduction Surgical Procedures; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Piperidines; Sulfonamides; Tumor Lysis Syndrome | 2022 |
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual | 2023 |